Chief, Division of Oncology
Professor of Medicine
Stanford University School of Medicine
A huge portion of the knowledge that could inform patient care is buried in patient electronic health records. Access to this information has been limited by the lack of integrated data on patient details, tumor biology, types of treatments, outcomes of therapy and overall survival. To overcome these barriers, Dr. Sledge and his team developed a research database called Oncoshare, which links information from electronic medical records (EMR) with information obtained from the statewide California Cancer Registry, and includes results of genetic tests for BRCA1 and BRCA2 and the widely used Oncotype Dx 21-gene recurrence score. This highly integrated database allows the researchers to evaluate treatments according to a patient’s unique molecular profile in order to discover new connections between specific treatments, breast cancer recurrence and survival in a large cohort of breast cancer patients.
In his current BCRF project, Dr. Sledge will utilize Oncoshare to determine the effectiveness of particular chemotherapy drugs, surgical and radiation techniques in different groups of patients, including those with inherited genetic characteristics (for example, mutations in BRCA1/2 or other breast cancer susceptibility genes) and/or specific breast cancer subtypes (particularly triple-negative breast cancer).
The goal of the project is to identify the best treatment strategies for specific subgroups of breast cancer patients. This unique "big data" approach will inform the development of large national cancer databases, as well as their application in advancing breast cancer care.
George W. Sledge Jr., MD, is Professor and Chief of Medical Oncology at Stanford University Medical Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He has published over 290 scientific articles spannning both laboratory and clinic.
Dr Sledge serves as Editor-in-Chief of Clinical Breast Cancer, and is Past President of the American Society of Clinical Oncology. He served as chair of the Breast Committee of the Eastern Cooperative Oncology Group from 2002 – 2009, where he led the development of nationwide clinical trials. Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of ‘Excellence for Medicine’, and was also the recipient of the 2006 Brinker Award for Scientific Distinction, the 2007 Breast Cancer Research Foundation's Jill Rose Award and the 2010 William L. McGuire Award from the San Antonio Breast Cancer Symposium.